Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | CCR4 | P51679 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.45 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16235261 | 0.84 | CCR4 (0.46) | KMT2ACCR4MEN1MAPT | |
| SCHEMBL16235195 | 0.75 | CCR4 (0.71) | CCR4 | |
| SCHEMBL16235480 | 0.75 | CCR4 (0.67) | CCR4 | |
| SCHEMBL16020314 | 0.72 | KDM4E (0.55) | KMT2AAKR1C3MEN1KDM4ETSHR | |
| SCHEMBL19558648 | 0.72 | KDM4E (0.52) | KMT2AAKR1C3MEN1KDM4ETSHR | |
| SCHEMBL4253424 | 0.71 | MEN1 (0.79) | KMT2AAKR1C3MEN1PFKFB3MAPT | |
| SCHEMBL16235419 | 0.71 | KDM4E (0.56) | KMT2AAKR1C3MEN1KDM4ETSHR | |
| SCHEMBL30702319 | 0.70 | PFKFB3 (0.76) | KMT2AAKR1C3MEN1KDM4ETSHR | |
| SCHEMBL30702318 | 0.70 | PFKFB3 (0.76) | KMT2AAKR1C3MEN1KDM4ETSHR | |
| SCHEMBL4063367 | 0.70 | PFKFB3 (0.76) | KMT2AAKR1C3MEN1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-11-13 | — | — | US | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2925743-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | Active Biotech AB (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | S100A9, S100B, S100A10 | KMT2A 3107/4885AKR1C3 4789/4885CCR4 4428/4885 |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | KMT2A 3107/4885AKR1C3 4789/4885CCR4 4428/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | KMT2A 4315/4885AKR1C3 4688/4885CCR4 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.